3D Printed Drugs Market is estimated to be $278 million in 2020, and would reach $522 million by 2030, growing at a CAGR of 6.5% from 2020 to 2030. U.S. market holds the highest market share in 2020.

3D printing drugs are drugs created by 3D printing technology used to treat patients suffering from dysphagia. 3D printing drugs have a porous structure that can collapse rapidly in the oral cavity. SPRITAM levetiracetam from Aprecia Pharmaceuticals Companies is the first 3D printing drug approved by the US Food and Drug Administration (FDA) in August 2015.

Download PDF Report Sample with statistical info @ https://www.alliedmarketresearch.com/request-sample/4508

The key players profiled in this report include
• Aprecia Pharmaceuticals
• GlaxoSmithKline Plc.
• Hewlett Packard Caribe
• BV LLC
• 3D Printer Drug Machine
• FabRx Ltd.

The organizations engaged in the research of 3D printed drugs included in this report are UCL School of Pharmacy, University of Glasgow, University College London, The University of Nottingham, and National University of Singapore.

Constant technological developments in 3D printing technique, rise in incidence of epilepsy cases, and increase in awareness about the 3D printing technology in the developing countries drive the growth of the market. However, lack of government regulations related to these drugs and adverse effects of 3D printed drugs are expected to limit the market growth.

The global 3D printed drugs market is analyzed based on forecast scenario such as low growth scenario, moderate growth scenario, and rapid growth scenario.

According to low growth scenario, the U.S. is anticipated to account for the highest market share in 2020, and rest of North America market is expected to grow at the highest rate, registering the CAGR of 5.1% by 2030.
Europe is estimated to account for four-sevenths share in 2020, and is expected to dominate the market throughout the forecast period, due to presence of well-established healthcare systems and increase in prevalence of dysphagia. In addition, increase in adoption of 3D printed drugs is anticipated to provide new growth opportunities for the key players in the European market. However, Asia-Pacific is projected to grow at the highest growth rate during the analysis period, owing to increase in healthcare expenditure, rise in awareness related to 3D printing technique, presence of large patient pool, and developments in healthcare infrastructure.